Use of a Smartphone-Based Medication Adherence Platform to Improve Outcomes in Uncontrolled Type 2 Diabetes Among Veterans: Prospective Case-Crossover Study (Preprint)
Authors: Rai Amneet , Riddle Mark , Mishra Rajendra , Nguyen Nhien , Valine Kelly , Fenney Megan 
Published: November 2022

BACKGROUND

Medication nonadherence is a problem that impacts both the patient and the health system.

OBJECTIVE

The objective of this study was to evaluate the impact of a novel smartphone app with patient-response-directed clinical intervention on medication adherence and blood glucose control in noninsulin-dependent patients with type 2 diabetes mellitus (T2DM).

METHODS

We enrolled 50 participants with T2DM not on insulin with smartphones from a rural health care center in Northern Nevada for participation in this case-crossover study. Participants underwent a standard of care arm and an intervention arm. Each study arm was 3 months long, for a total of 6 months of follow-up. Participants had a hemoglobin A<sub>1c</sub> (HbA<sub>1c</sub>) lab draw at enrollment, 3 months, and 6 months. Participants had monthly “medication adherence scores” (MAS) and “Self-Efficacy for Appropriate Medication Use Scale” (SEAMS) questionnaires completed at baseline and monthly for the duration of the study. Our primary outcomes of interest were the changes in HbA<sub>1c</sub> between study arms. Secondary outcomes included the evaluation of the difference in the proportion of participants achieving a clinically meaningful reduction in HbA<sub>1c</sub> and the difference in the number of participants requiring diabetes therapy escalation between study arms. Exploratory outcomes included the analysis of the variation in medication possession ratio (MPR), MAS, and SEAMS during each study arm.

RESULTS

A total of 30 participants completed both study arms and were included in the analysis. Dropouts were higher in participants enrolled in the standard of care arm first (9/25, 36% vs 4/25, 16%). Participants had a median HbA<sub>1c</sub> of 9.1%, had been living with T2DM for 6 years, had a median age of 66 years, and had a median of 8.5 medications. HbA<sub>1c</sub> reduction was 0.69% in the intervention arm versus 0.35% in the standard of care arm (<i>P</i>=.30). A total of 70% (21/30) of participants achieved a clinically meaningful reduction in HbA<sub>1c</sub> of 0.5% in the app intervention arm versus 40% (12/30) in the standard of care arm (odds ratio 2.29, 95% CI 0.94-5.6; <i>P</i>=.09). Participants had higher odds of a therapy escalation while in the standard of care arm (18/30, 60% vs 5/30, 16.7%, odds ratio 4.3, 95% CI 1.2-15.2; <i>P</i>=.02). The median MPR prior to enrollment was 109%, 112% during the study’s intervention arm, and 102% during the standard of care arm. The median real-time MAS was 93.2%. The change in MAS (1 vs –0.1; <i>P</i>=.02) and SEAMS (1.9 vs –0.2; <i>P</i>&lt;.001) from baseline to month 3 was higher in the intervention arm compared to standard of care.

CONCLUSIONS

A novel smartphone app with patient-response-directed provider intervention holds promise in the ability to improve blood glucose control in complex non–insulin-dependent T2DM and is worthy of additional study.